<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9830">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05689333</url>
  </required_header>
  <id_info>
    <org_study_id>CBCC/2022/009</org_study_id>
    <nct_id>NCT05689333</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Performance of the Vista Probe for Vitrectomy Surgery</brief_title>
  <official_title>A Prospective, Single-arm, Non-comparative, Open-label, Monocular, Post Approval Study to Assess Safety and Device Performance of the Vista Vitrectomy Probe During Vitrectomy Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VISTA Ophthalmics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CBCC Global Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VISTA Ophthalmics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-arm, non-comparative, open-label, monocular, post approval&#xD;
      study to assess safety and device performance of the Vista Vitrectomy Probe during vitrectomy&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2022</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of post-operative rates of retinal tears</measure>
    <time_frame>Month 1</time_frame>
    <description>Calculate the incidence of post-operative rates of retinal tears</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of retinal detachment</measure>
    <time_frame>Month 1</time_frame>
    <description>Calculate the incidence of post-operative retinal detachment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of sclerotomy complications like leakage</measure>
    <time_frame>Month 1</time_frame>
    <description>Calculate the incidence of post-operative sclerotomy complications like leakage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of ocular hypotony</measure>
    <time_frame>Month 1</time_frame>
    <description>Calculate the incidence of post-operative ocular hypotony</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of choroidal detachment</measure>
    <time_frame>Month 1</time_frame>
    <description>Calculate the incidence of post-operative choroidal detachment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of visually significant vitreous hemorrhage</measure>
    <time_frame>Month 1</time_frame>
    <description>Calculate the incidence of post-operative visually significant vitreous hemorrhage (visual acuity defined by counting fingers or worse)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of endophthalmitis</measure>
    <time_frame>Month 1</time_frame>
    <description>Calculate the incidence of post-operative endophthalmitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgeon- will assess device adequacy for removal of vitreous</measure>
    <time_frame>Day 0 (Operative Visit)</time_frame>
    <description>Surgeon-assess device adequacy for removal of vitreous will be summarized using counts and percentages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of eyes with clinical evidence of incomplete vitrectomy, such as vitreous strands or pupil peaking</measure>
    <time_frame>Days1, 7, 30 &amp; 90</time_frame>
    <description>Percentage of eyes with clinical evidence of incomplete vitrectomy, such as vitreous strands or pupil peaking, at any post-operative visit will be summarized using counts and percentages</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Vitrectomy</condition>
  <arm_group>
    <arm_group_label>27 GA Vista Ophthalmics vitrector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The vitrectomy will be performed through the pars plana using the 27 GA Vista Ophthalmics vitrector.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vista Vitrectomy Probe</intervention_name>
    <description>Vitrectomy will be performed through 27 GA Vista Ophthalmics vitrector</description>
    <arm_group_label>27 GA Vista Ophthalmics vitrector</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participant with age â‰¥ 18 years at the time of screening.&#xD;
&#xD;
          -  Subject must have a clinical indication for anterior vitrectomy.&#xD;
&#xD;
          -  Subjects must be able to understand and voluntarily provide written informed consent&#xD;
             before screening, following an explanation of the nature and purpose of this study.&#xD;
&#xD;
          -  Subjects must be willing and able to comply with all treatment and follow-up study&#xD;
             procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have experienced any significant trauma in the operative eye within the&#xD;
             past month.&#xD;
&#xD;
          -  Subjects with any active ocular infection or history of any herpetic infection that&#xD;
             has cleared less than one month prior to the pre-operative visit.&#xD;
&#xD;
          -  Subjects with prior history of uncontrolled glaucoma or uveitis refractory to&#xD;
             treatment or ocular hypertension (IOP&gt;30mm Hg) in study eye.&#xD;
&#xD;
          -  Subjects with any medical condition (e.g., uncontrolled diabetes) that, based on the&#xD;
             Investigator's medical judgment, poses a concern for the subjects' safety.&#xD;
&#xD;
          -  Female subjects of child bearing potential with positive urine pregnancy test&#xD;
&#xD;
          -  Subjects who have participated in any drug or device clinical investigation within 30&#xD;
             days prior to entry into or during this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Knowles</last_name>
    <role>Study Chair</role>
    <affiliation>VISTA Ophthalmics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jayadev Sureddi</last_name>
    <phone>+1 661 616 6453</phone>
    <email>jayadev.sureddi@cbcc.global</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eldho Jose</last_name>
    <email>eldho.jose@cbcc.global</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CBCC Global Research Site:003</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CBCC Global Research Site:002</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CBCC Global Research Site:001</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CBCC Global Research Site:004</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>December 22, 2022</study_first_submitted>
  <study_first_submitted_qc>January 16, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2023</study_first_posted>
  <last_update_submitted>April 25, 2023</last_update_submitted>
  <last_update_submitted_qc>April 25, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitrectomy Probe</keyword>
  <keyword>Vitreous aspiration &amp; cutting</keyword>
  <keyword>Dissect tissue in the eye</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

